


9 January 2020  
ASX Code: MXC

## MGC Pharma crosses 2,000 prescription milestone and first shipment arrived in Brazil

**MGC Pharmaceuticals Ltd (ASX: MXC, 'MGC Pharma' or 'the Company')**, a European based 'Seed to Medicine' bio-pharma company specialising in the production and development of phytocannabinoid-derived medicines, is pleased to announce that it has passed 2,000 prescribed units threshold of its standardised, affordable cannabinoid medicines. This increase has been achieved from patients in Australia, the United Kingdom and with the recent additions of new patient special access approved markets of Brazil and Ireland following the recent approval for the sale of MGC Pharma products in these countries.

Furthermore, MGC Pharma can confirm that its first shipment has arrived in Brazil following a maiden purchase order from ONIX Empreendimentos e Participações ('Onix') in November 2019.



### Key Highlights:

- MGC Pharma passes 2,000 prescriptions in the UK, Australia, Brazil and Ireland, with 262 new patients added in December
- The over 2,000 prescriptions issued to date are for both CannEpiL® and the Company's high CBD medicine MXP100
- Over 800 patients now prescribed MGC Pharma products
- 33% of MXP100 and 43% of CannEpiL® are repeat prescriptions, these numbers are expected to increase as MGC Pharma further establishes a market presence and knowledge of Company's products increases amongst healthcare professionals
- Majority of the prescriptions have been issued in Australia to date, with the balance from initial prescriptions issued across the UK, Brazil and Ireland
- Near term revenue continues to increase as prescription numbers grow in targeted markets
- The Company's recently launched proprietary affordable prescription CBD medicine line, owned 100% and branded as Mercury Pharma for the Australian and New Zealand Markets, will also provide an immediate new revenue stream during Q1 2020

A  
S  
X  
  
R  
E  
L  
E  
A  
S  
E

**Roby Zomer, Co-founder and Managing Director of MGC Pharma, commented:** “MGC Pharma made terrific progress in 2019, having grown from just 100 prescriptions starting in August 2019, to more than 2,000 by the start of the calendar year. I am confident that this rapid growth trajectory will continue in 2020 as our products are now available on three continents and the prescription numbers are projected to increase as the knowledge of MGC Pharma’s medicines improves amongst healthcare professionals.

“The first delivery of products to Brazil and the launch of our new Mercury Pharma medicine line for the Australian and New Zealand markets are further reasons to be optimistic as they will have a positive impact on the Company’s future revenue generation.

“Last year we laid a very solid foundation for the Company and in 2020 we shall build on it as we plan to continue to grow product sales, expand distribution to new territories, advance our clinical trials and commence construction at our production facility in Malta. We expect a lot of near-term positive news flow and I look forward to updating our shareholders on our progress.”

### **Mercury Pharma Overview**

MGC Pharma has launched a new proprietary affordable prescription CBD medicine line, specifically for the Australian and New Zealand markets, to be branded as Mercury Pharma, 100% owned by MGC Pharma, with the first product being “Mercury Pharma 100” (‘MP100’). MP100, a 100mg/mL CBD solution, will be prescribed by healthcare professionals in Australia and New Zealand, initially distributed by Australian medicinal cannabis distribution and logistics specialist Cannvalate Pty Ltd and Health House International Pty Ltd in due course. Purchase orders for 2,000 units of MP100 have been received and will be delivered in January and February 2020, pending the granting of Import Permits by the Australian Office of Drug Control, which will have an immediate and very positive impact on the Company’s Q1 2020 revenues.

### **Further Information**

CannEpi<sup>®</sup>, used in the treatment of drug-resistant epilepsy, and MXP100, is recommended for mild neurological disorders, inflammatory issues and for hepatoma patients are both proprietary MGC Pharma products that have been developed internally through the Company’s Research and Development division and progressed through to commercialisation. This is in line with the Company’s ‘Seed to Medicine’ strategy with the Company owning all the intellectual property through each stage of a product’s development, from the genetics to finished pharmaceutical grade product.

The Company continues to work closely with its designated distributors to onboard further clinics, in addition to independent medical professionals, in each region increasing patient access to its phytocannabinoid-derived medicines under the relevant legislation in each jurisdiction.

--Ends--

**Authorised for release by the Board, for further information please contact:**

#### **UK IR/Media Advisors**

Catherine Leftley/Megan Dennison  
St Brides Partners Ltd  
+44 (0) 207 236 1177  
[megan@stbridespartners.co.uk](mailto:megan@stbridespartners.co.uk)  
[catherine@stbridespartners.co.uk](mailto:catherine@stbridespartners.co.uk)

#### **MGC Pharmaceuticals Ltd**

Brett Mitchell  
Executive Chairman  
+61 8 6382 3390  
[info@mgcpharma.com.au](mailto:info@mgcpharma.com.au)

## About MGC Pharma

MGC Pharmaceuticals Ltd (ASX: MXC, OTCQB: MGCLF) is a European based bio-pharma company supplying phytocannabinoid-derived medicines to patients globally. The Company's founders were key figures in the global medical cannabis industry and the core business strategy is to develop and supply high quality phytocannabinoid derived medicines for the growing demand in the medical markets in Europe, North America and Australasia. MGC Pharma has a robust product offering targeting three widespread medical conditions - epilepsy, dementia and IBS – and has further products in the development pipeline.

Employing its 'Seed to Medicine' strategy, MGC Pharma has partnered with renowned institutions and academia to optimise cultivation and the development of targeted phytocannabinoid derived medicines products prior to production in the Company's EU-GMP Certified manufacturing facility. MGC Pharma has a number of research collaborations with world renowned academic institutions, and recent research conducted in collaboration with the National Institute of Biology and University Medical Centre Ljubljana, highlighted the positive impact of using specific phytocannabinoid formulations in the treatment of glioblastoma, the most aggressive and so far therapeutically resistant primary brain tumour.

MGC Pharma has a growing patient base in Australia and the UK and has a global distribution footprint via an extensive network of commercial partners meaning that it is poised to supply the global market. In order to meet the demands of becoming a key global supplier the company is constructing a 15,720m<sup>2</sup> GMP state of the art facility in Malta.

Follow us through our social media channels    